Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor for Robust Tumor Angiogenesis Inhibition

Executive Summary: Anlotinib hydrochloride (CAS 1058157-76-8) is a novel small-molecule inhibitor that blocks VEGFR2, PDGFRβ, and FGFR1 with nanomolar potency, resulting in pronounced anti-angiogenic activity in vitro and in vivo (Lin et al., 2018). Compared to sunitinib, sorafenib, and nintedanib, anlotinib demonstrates superior inhibition of endothelial cell migration and tube formation. It exhibits favorable pharmacokinetics with high plasma protein binding and broad tissue distribution, including accumulation in tumor and lung tissues. APExBIO's anlotinib (hydrochloride) enables rigorous pathway dissection and reproducible anti-angiogenic assay results for cancer research (APExBIO). Safety studies show high LD₅₀ and low systemic toxicity in standard preclinical models.

Biological Rationale

Angiogenesis, the formation of new blood vessels from the existing vasculature, is essential for tumor growth and metastasis (Lin et al., 2018). Tumor cells secrete pro-angiogenic cytokines such as VEGFA, PDGF-BB, and FGF-2 to stimulate endothelial cell migration, proliferation, and neovascularization. The primary effectors—VEGFR2, PDGFRβ, and FGFR1—are tyrosine kinase receptors that activate pathways like ERK, promoting capillary tube formation and tumor perfusion. Inhibiting these kinases interrupts nutrient supply and impedes tumor expansion. Multi-targeted tyrosine kinase inhibitors (TKIs) that block several angiogenic pathways simultaneously, such as anlotinib hydrochloride, are more effective in suppressing tumor angiogenesis compared to single-target agents (see previous overview; this article provides updated quantitative benchmarks and workflow optimization guidance).

Mechanism of Action of Anlotinib (hydrochloride)

Anlotinib hydrochloride is a small-molecule, multi-target TKI that directly inhibits the kinase activity of VEGFR2, PDGFRβ, and FGFR1 with IC₅₀ values of 5.6 ± 1.2 nM, 8.7 ± 3.4 nM, and 11.7 ± 4.1 nM, respectively (Lin et al., 2018, Table 1). This inhibition blocks the phosphorylation and downstream signaling of these receptors, especially the ERK pathway, which is critical for endothelial cell proliferation and migration. Mechanistically, anlotinib disrupts VEGF/PDGF-BB/FGF-2-induced migration of human vascular endothelial cells (EA.hy 926) and impairs capillary-like tube formation in a concentration-dependent manner. It also reduces microvessel density in ex vivo rat aortic ring and chicken chorioallantoic membrane (CAM) assays. Compared to sunitinib, sorafenib, and nintedanib, anlotinib demonstrates superior inhibition of pro-angiogenic signaling and functional endpoints in both cell-based and tissue assays (Lin et al., 2018).

Evidence & Benchmarks

• Anlotinib inhibits VEGF-induced endothelial cell migration with an IC₅₀ of 5.6 ± 1.2 nM (EA.hy 926 cell assay, 24 h, 37°C, 5% CO₂) (DOI).
• It blocks PDGF-BB- and FGF-2-driven migration and tube formation with IC₅₀ values of 8.7 ± 3.4 nM (PDGFRβ) and 11.7 ± 4.1 nM (FGFR1) (DOI).
• In ex vivo rat aortic ring and CAM models, anlotinib reduces microvessel density more effectively than sunitinib, sorafenib, or nintedanib (p < 0.01; CAM assay, 48 h, 37°C) (DOI).
• Anlotinib demonstrates oral bioavailability of 28–58% in rats and 41–77% in dogs, with high plasma protein binding (93% in humans) (DOI).
• In 14-day oral toxicity studies, anlotinib's LD₅₀ is 1735.9 mg/kg, with minimal systemic or genetic toxicity noted (DOI).

For a mechanistic deep dive and emerging research directions, see this advanced mechanistic review—the present article adds comparative efficacy and workflow integration data not covered previously.

Applications, Limits & Misconceptions

Anlotinib hydrochloride is primarily used for research on tumor angiogenesis inhibition, cellular signaling pathway dissection, and anti-angiogenic assay development. Its superior selectivity for VEGFR2, PDGFRβ, and FGFR1 makes it a preferred tool for studying the ERK signaling pathway and evaluating anti-cancer compounds in preclinical workflows (see detailed workflow strategies; this article expands with toxicity and PK data for protocol planning). It is not intended for diagnostic or therapeutic use in humans. Below is a clarification of common boundaries:

Common Pitfalls or Misconceptions

• Anlotinib is not suitable for direct clinical use: It is strictly for research applications; clinical formulations and dosing require separate validation (APExBIO).
• Not a pan-kinase inhibitor: Its activity is selective for VEGFR2, PDGFRβ, and FGFR1, with minimal off-target inhibition at recommended concentrations (DOI).
• Results may vary across cell types: Efficacy is best characterized in endothelial cells (EA.hy 926); other cell lines may show differential sensitivity.
• Storage and handling matter: The compound should be stored at -20°C; repeated freeze-thaw cycles can reduce potency (APExBIO).
• Limited efficacy in non-angiogenic tumor models: Tumors not reliant on angiogenesis may not respond to anlotinib-based interventions.

Workflow Integration & Parameters

APExBIO provides anlotinib hydrochloride (C8688) for research use, supplied as a stable powder to be dissolved in DMSO or other compatible solvents. Recommended concentration ranges for in vitro studies are 1–100 nM, depending on assay sensitivity. For endothelial cell migration and capillary tube formation assays, 5–20 nM yields robust inhibition within 24–48 hours at 37°C, 5% CO₂, in standard EGM-2 media. For in vivo or ex vivo studies, dosing regimens should be calibrated based on tissue distribution and species-specific pharmacokinetics—rat and dog models demonstrate reliable oral absorption and broad tissue distribution, including tumor, lung, liver, and kidney (Lin et al., 2018). The compound’s metabolic profile is dominated by CYP3A-mediated hydroxylation and dealkylation, with minimal parent drug excreted. For troubleshooting and advanced optimization, see this workflow guide; the present article includes new comparative PK and toxicity data.

Conclusion & Outlook

Anlotinib hydrochloride establishes a new benchmark in anti-angiogenic research as a multi-target tyrosine kinase inhibitor with nanomolar potency against VEGFR2, PDGFRβ, and FGFR1. Its superior efficacy in inhibiting tumor angiogenesis and favorable safety profile make it a preferred tool for dissecting tyrosine kinase signaling pathways in cancer models. By providing reliable and reproducible results across standard endothelial cell and tissue assays, anlotinib supports the development of next-generation anti-cancer strategies. For detailed product information and ordering, visit Anlotinib (hydrochloride) at APExBIO.